BeiGene (ONC) AI Stock Analysis

• Market Cap: $33.71B
• Dividend Yield: N/A
• Average Volume (3M): 321.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 51.16%
• EPS Growth: 50.65%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.00
• Shares Outstanding: 109,600,150
• 10 Day Avg. Volume: 393,714
• 30 Day Avg. Volume: 321,817
• PEG Ratio: -5.38
• Price to Book (P/B): 67.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -150.01
• Enterprise Value/Market Cap: 8.66
• Enterprise Value/Revenue: 20.27
• Enterprise Value/Gross Profit: 82.42
• Enterprise Value/Ebitda: -143.50
• 1Y Price Target: $331.94
• Price Target Upside: 37.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 54 Neutral
• Price Target: $246.00 ▲(1.99%Upside)

The most significant factor in the stock's score is the company's impressive revenue growth and recent GAAP profitability, as highlighted in the earnings call. However, ongoing profitability issues and valuation concerns weigh heavily on the overall score. Technical indicators further suggest bearish momentum, contributing to a moderate score.

Positive Factors

Financial Performance

The first-ever quarterly GAAP profitability marks a significant milestone for BeiGene, driven by strong top-line growth and enhanced operating leverage.

Market Performance

Zanubrutinib captured a substantial share of the BTK inhibitor market in China, indicating strong competitive positioning.

Product Pipeline

BeOne’s rich and diversified pipeline could support its long-term growth.

Negative Factors

Product Licensing

The USPTO invalidated all claims on ABBV's '803 patent, removing a ~$2.5 billion cash outflow assumption for potential settlement fees.

Product Performance

Sales of some of the licensed-in products like denosumab experienced a decline, highlighting areas of concern in product performance.

BeiGene Business Overview & Revenue Model

Company Description

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

How the Company Makes Money

BeiGene makes money primarily through the development, production, and commercialization of its oncology drugs. The company's revenue model is based on the sale of its proprietary cancer treatments, which are marketed and distributed in multiple regions, including the United States, China, and other international markets. Key revenue streams include product sales, which are driven by the successful approval and market penetration of its drugs. Additionally, BeiGene partners with other pharmaceutical companies and research institutions to co-develop and commercialize cancer therapies, which can result in milestone payments, royalties, and shared profits. Significant partnerships, such as those with Amgen and Novartis, contribute to its earnings by expanding its product portfolio and global reach.

BeiGene Financial Statement Overview

Summary

BeiGene shows a strong revenue growth trajectory but faces ongoing operational challenges with persistent negative net income and high operational costs. Although the company maintains a solid equity position, profitability remains a major concern.

Income Statement

BeiGene shows a strong revenue growth trajectory with a significant increase from $308.9M in 2020 to $4.18B in TTM 2025. Gross profit margins have improved vastly; however, the company has consistently reported negative EBIT and net income, indicating ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company maintains a solid equity position with an improving debt-to-equity ratio, indicating disciplined financial management amidst high growth. The equity ratio suggests strong asset backing, though consistent negative net income impacts ROE negatively.

Cash Flow

Operating cash flow has shown improvement in TTM 2025, yet free cash flow remains negative, reflecting substantial capital expenditures and investments. The cash position is strong, providing a buffer for ongoing cash outflows, but profitability remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.18B	3.81B	2.46B	1.42B	1.18B	308.87M
Gross Profit	3.54B	3.22B	2.08B	-511.06M	-447.86M	-1.06B
EBITDA	-117.30M	-396.44M	-1.12B	-1.72B	-1.39B	-1.63B
Net Income	-392.37M	-644.79M	-881.71M	-2.00B	-1.41B	-1.60B
Balance Sheet
Total Assets	5.84B	5.92B	5.81B	6.38B	8.65B	5.60B
Cash, Cash Equivalents and Short-Term Investments	2.52B	2.63B	3.17B	4.53B	6.62B	4.66B
Total Debt	996.83M	1.08B	930.18M	596.67M	694.64M	561.96M
Total Liabilities	2.34B	2.59B	2.27B	2.00B	2.40B	1.73B
Stockholders Equity	3.50B	3.33B	3.54B	4.38B	6.24B	3.87B
Cash Flow
Free Cash Flow	-240.47M	-669.77M	-1.75B	-1.97B	-1.61B	-1.51B
Operating Cash Flow	212.02M	-140.63M	-1.16B	-1.50B	-1.30B	-1.28B
Investing Cash Flow	-460.46M	-548.35M	60.00M	1.08B	640.66M	-3.17B
Financing Cash Flow	-2.62M	193.45M	416.48M	-18.97M	3.64B	5.20B

BeiGene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 241.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONC, the sentiment is Negative. The current price of 241.2 is below the 20-day moving average (MA) of 257.78, below the 50-day MA of 247.16, and above the 200-day MA of 225.67, indicating a neutral trend. The MACD of 2.42 indicates Positive momentum. The RSI at 42.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ONC.

BeiGene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	71 Outperform	$10.38B	20.07	9.64%	―	17.99%	152.10%
BIIB	69 Neutral	$18.65B	12.53	9.19%	―	1.25%	26.10%
ARGX	68 Neutral	$34.51B	40.32	17.33%	―	78.01%	―
BNTX	58 Neutral	$25.19B	―	-3.87%	―	0.58%	-764.64%
ONC	54 Neutral	$33.71B	―	-11.44%	―	51.16%	50.65%
BIO	53 Neutral	$6.55B	―	-27.51%	―	-2.46%	-637.11%
Sector *	46 Neutral	C$190.36M	-4.25	-8.56%	3.10%	13.57%	-1.98%

BeiGene Corporate Events

BeiGene Holds Annual Shareholders Meeting, Key Resolutions Passed

On May 21, 2025, BeiGene, Ltd. held its Annual Meeting of Shareholders, where approximately 70% of the outstanding ordinary shares were represented. Key resolutions passed included the re-election of several directors, the ratification of Ernst & Young as auditors, and the approval of mandates for share issuance and repurchase. These decisions are poised to influence BeiGene’s strategic direction and operational flexibility, potentially impacting shareholder value and market positioning.

The most recent analyst rating on (ONC) stock is a Buy with a $317.00 price target. To see the full list of analyst forecasts on BeiGene stock, see the ONC Stock Forecast page.